Tyra Biosciences shares surge 10.17% intraday as strong cash position and progress in FGFR-targeting cancer drug pipeline boost optimism.

Tyra Biosciences surged 10.17% intraday, driven by the company’s announcement of a 2025 annual report showing $25.6 million in cash and equivalents with no debt. Based on an estimated $95 million annual burn rate, the cash runway extends approximately 2.7 years, sufficient to support operations until 2027. The company specializes in developing precision oncology drugs targeting FGFR, with core programs—dabogratinib, TYRA-430, and TYRA-200—all in clinical stages. TYRA-430 initiated Phase I trials in April 2025, and TYRA-200 is in Phase I for FGFR2-driven cholangiocarcinoma.